Avalo Therapeutics, Inc. AVTX

Rank #2514 · Nasdaq · $0.4B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

9.7

P/E

-10.7

P/B

51.60

ROE

-481.0%

Op. Margin

-15535.6%

Debt Ratio

242%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -10.7x, P/B 51.60x. Ranks in the top 88% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -481.0%. Ranks in the top 99% of the universe.

Safety ★★☆☆☆

Weak

Debt ratio 242%. Ranks in the top 67% of the universe. Above 200% signals meaningful leverage risk.

Growth ★☆☆☆☆

Poor

Revenue decline of 77.1% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	–	$-0.0B	$-0.0B	$-0.0B	–	-91
2016	–	$-0.0B	$-0.0B	$-0.0B	–	-48
2017	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-21
2018	$0.0B	$0.0B	$0.0B	$0.0B	49.9	7221
2019	$0.0B	$-0.0B	$-0.0B	$0.0B	-503.4	177
2020	$0.0B	$-0.0B	$-0.0B	$0.0B	-239.1	72
2021	$0.0B	$-0.1B	$-0.1B	$0.0B	-1087.4	91
2022	$0.0B	$-0.1B	$-0.1B	$0.0B	-1521.6	233
2023	$0.0B	$-0.0B	$-0.0B	$0.0B	-207.4	192
2024	$0.0B	$-0.0B	$-0.0B	$-0.0B	-1421.6	-125
2025	$0.0B	$-0.1B	$-0.0B	$0.0B	-15535.6	242